# Nijmegen nursing home allows controlled drug and alcohol use for elderly with addictions > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/nijmegen-nursing-home-allows-controlled-drug-and-alcohol-use-for-elderly-with-addictions/ > **Published:** 2026-06-15T07:15:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:23:29-04:00 > **Clinical Summary:** How elderly addiction harm reduction and supervised cannabis use integrate into palliative nursing care—clinical ethics and outcomes. --- ✦ New CED Clinical Relevance #47 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. AgingPolicyMental HealthSafetyDosingAnxietySleep Why This Matters This approach demonstrates that [harm reduction](https://cedclinic.com/adolescent-cannabis-use-psychotic-disorders-risk/) principles can improve [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) and treatment engagement in elderly patients with substance use disorders who have limited life expectancy, shifting clinical focus from abstinence to functional wellbeing. Clinicians caring for older adults with addiction histories should consider whether supervised, controlled use might reduce dangerous withdrawal effects, medication interactions, and behavioral complications that often complicate end-of-life care. The model suggests regulatory and institutional flexibility around substance use policies could allow more individualized, patient-centered treatment plans for this vulnerable population. Clinical Summary A nursing home in Nijmegen, Netherlands has implemented a [harm reduction](https://cedclinic.com/adolescent-cannabis-use-psychotic-disorders-risk/) model that permits supervised [cannabis and alcohol](https://cedclinic.com/can-you-mix-weed-and-alcohol/) use for elderly residents with established substance use disorders, integrating substance use into standard care protocols rather than enforcing abstinence. This approach reflects a pragmatic recognition that complete cessation may be unrealistic or contraindicated in end-of-life or palliative settings, and that [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) considerations may outweigh abstinence-focused goals in geriatric populations. The supervised integration of substance use into daily routines allows clinicians to monitor consumption patterns, manage drug interactions with other medications, and prevent dangerous withdrawal syndromes while maintaining overall health and dignity. This model has potential implications for how clinicians approach substance use in elderly patients, particularly those with comorbidities or limited life expectancy where [harm reduction](https://cedclinic.com/adolescent-cannabis-use-psychotic-disorders-risk/) rather than abstinence may align better with individualized treatment goals. Clinicians caring for elderly patients with long-standing cannabis or alcohol use should consider whether strict prohibition serves patients’ best interests or whether supervised, integrated approaches might improve compliance with other medical care and overall [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) in appropriate cases. Dr. Caplan’s Take “What we’re seeing in Nijmegen is a pragmatic harm-reduction approach in a vulnerable population, and while I appreciate the humanistic intent, we really need peer-reviewed data on safety outcomes and cognitive effects in elderly residents before we can say whether this model actually improves quality of life or introduces unrecognized risks.” Clinical Perspective 💊 This Dutch model of managed substance use in long-term care settings challenges traditional abstinence-based approaches and raises important questions about harm reduction principles in geriatric populations. While integrating supervised cannabis and other substance access may improve quality of life, medication adherence, and reduce distress in elderly residents with established addiction histories, clinicians should recognize significant practical and ethical complexities: cognitive decline may impair informed consent, polypharmacy interactions with cannabis remain understudied in older adults, and facility-level implementation requires robust medical oversight and clear protocols that many institutions lack. The approach also highlights potential confounders such as selection bias toward motivated facilities and resident populations, as well as variable legal frameworks across jurisdictions that limit generalizability. For practitioners in standard geriatric settings, this model suggests the value of assessing substance use patterns in elderly patients not as mere behavioral problems to eliminate, but as potential quality-of-life factors to address compassionately 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/medical-illness/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Nijmegen%20nursing%20home%20allows%20controlled%20drug%20and%20alcohol%20use%20for%20elderly%20with%20addictions%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59114)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59114)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Nijmegen%20nursing%20home%20allows%20controlled%20drug%20and%20alcohol%20use%20for%20elderly%20with%20addictions%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59114)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://nltimes.nl/2026/06/15/nijmegen-nursing-home-allows-controlled-drug-alcohol-use-elderly-addictions](https://nltimes.nl/2026/06/15/nijmegen-nursing-home-allows-controlled-drug-alcohol-use-elderly-addictions) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).